Diagnóstico e intervención médica en la debilidad muscular adquirida / Diagnóstico e intervenção médica na fraqueza muscular adquirida / Diagnosis and medical intervention in acquired muscle weakness

Introducción: la debilidad adquirida del paciente en la Unidad de Terapia Intensiva es un problema que le provoca deficiencias en su estado físico y funcional. Objetivo: sistematizar contenidos esenciales relacionados con la debilidad adquirida del paciente en la Unidad de Terapia Intensiva. Método: en el Hospital General Docente Dr. Agostinho Neto, entre enero y septiembre de 2019 se hizo una revisión narrativa sobre el tema a través de una búsqueda en bases de datos electrónicas (Biblioteca Virtual en Salud, LILACS, PubMed, SciELO, RedALyC, Scopus). Se localizaron 135 documentos y se eligieron 25 relevantes para el objetivo de la revisión. La información se estructuró en los siguientes aspectos sobre la debilidad adquirida del paciente en la Unidad de Terapia Intensiva: definición, antecedentes históricos, epidemiología, fisiopatología, diagnóstico e intervención médica. Resultados: se identificaron controversias sobre los criterios diagnósticos precisos, el protocolo de actuación para su prevención y rehabilitación y la carencia de un instrumento para estratificar el riesgo de esta complicación. Conclusiones: se sistematizaron las bases para la preparación de los profesionales en el diagnóstico, la prevención de la debilidad adquirida del paciente en la Unidad de Terapia Intensiva y su rehabilitación(AU)

Introduction: the patient's acquired weakness in the Intensive Care Unit is a problem that causes deficiencies in his physical and functional state. Objective: systematize essential contents related to the patient's acquired weakness in the Intensive Care Unit. Method: in the General Teaching Hospital "Dr. Agostinho Neto", between January and September 2019, a narrative review of the subject was made through a search in electronic databases (Virtual Health Library, LILACS, PubMed, SciELO, RedALyC, Scopus). 135 documents were located and 25 relevant for the purpose of the review were chosen. The information was structured in the following aspects about the patient's acquired weakness in the Intensive Care Unit: definition, historical background, epidemiology, pathophysiology, diagnosis and medical intervention. Results: controversies were identified about the precise diagnostic criteria, the protocol of action for its prevention and rehabilitation and the lack of an instrument to stratify the risk of this complication. Conclusions: the bases for the preparation of the professionals in the diagnosis, the prevention of the acquired weakness of the patient in the Intensive Care Unit and its rehabilitation were systematized(AU)

Introdução: a fragilidade adquirida pelo paciente na Unidade de Terapia Intensiva é um problema que causa deficiências no seu estado físico e funcional. Objetivo: sistematizar conteúdos essenciais relacionados à fraqueza adquirida do paciente na Unidade de Terapia Intensiva. Método: no Hospital Geral de Ensino "Dr. Agostinho Neto", entre janeiro e setembro de 2019, foi realizada uma revisão narrativa do assunto através de uma busca em bases de dados eletrônicas (Biblioteca Virtual em Saúde, LILACS, PubMed, SciELO, RedALyC, Scopus). Foram localizados 135 documentos e escolhidos 25 relevantes para a finalidade da revisão. As informações foram estruturadas nos seguintes aspectos sobre a fragilidade adquirida pelo paciente na Unidade de Terapia Intensiva: definição, histórico, epidemiologia, fisiopatologia, diagnóstico e intervenção médica. Resultados: foram identificadas controvérsias sobre os critérios diagnósticos precisos, o protocolo de ação para sua prevenção e reabilitação e a falta de um instrumento para estratificar o risco dessa complicação. Conclusões: foram sistematizadas as bases para o preparo dos profissionais no diagnóstico, a prevenção da fragilidade adquirida do paciente na Unidade de Terapia Intensiva e sua reabilitação(AU)

Comparação da força muscular respiratória entre os subgrupos de fragilidade em idosas da comunidade / Comparison of respiratory muscle strength between fragility subgroups in community elderly / Comparación de la fuerza muscular respiratoria entre los subgrupos de fragilidad en añosas de la comunidad

A fragilidade é composta por um tripé constituído por: sarcopenia, disfunção imunológica e desregulação neuroendócrina. A sarcopenia é definida como uma diminuição na força e na potência muscular, sendo que os músculos respiratórios também são afetados. O objetivo foi comparar a força muscular respiratória (FMR) em idosas residentes na comunidade, classificadas como não frágeis (NF), pré-frágeis (PF) e frágeis (F) e correlacionar a FMR com a força de preensão manual (FPM). O estudo foi do tipo transversal, com uma amostra de conveniência composta por 106 idosas. As participantes foram classificadas quanto ao fenótipo de fragilidade. A FMR foi avaliada por meio da pressão inspiratória máxima (PImáx) e da pressão expiratória máxima (PEmáx). Foram encontradas diferenças significativas da FMR entre os grupos NF e F (PImáx: p=0,001 e PEmáx: p<0,001) e entre os grupos PF e F (PImáx: p<0,001 e PEmáx: p<0,001). Em relação à FPM, foram observadas diferenças significativas entre todos os grupos (p<0,001). Houve correlação entre FMR e FPM apenas no grupo frágil. Desta forma, a FPM pode ser importante na prática clínica para diferenciar os subgrupos de fragilidade e identificar a perda de força muscular, incluindo a perda da FMR...

The fragility consist in a tripod comprising: sarcopenia, immune dysregulation, and neuroendocrine dysfunction. Sarcopenia is defined as a decrease in strength and muscle power, so that the respiratory muscles are also affected. The aim was to compare respiratory muscle strength (RMS) in elderly community residents, classified as nonfrail (NF), pre frail (PF) and frail (F), and correlate RMS with the handgrip strength (HS). The study was cross-sectional, with a convenience sample of 106 elderly women. Participants were classified according to the phenotype of frailty. The RMS was assessed by maximal inspiratory pressure (MIP) and maximum expiratory pressure (MEP). Significant differences were found in RMS between groups NF and F (MIP: p=0.001 and MEP: p<0.001) and between groups PF and F (MIP: p<0.001 and MEP: p<0.001). In relation to HS, significant differences were observed between all groups (p<0.001). There was correlation between HS and RMS only in the frail group. Thus, the HS may be important in the clinical evaluation to differentiate subgroups of fragility and identify the loss of muscle strength, including the loss of RMS...

La fragilidad está compuesta por un trípode constituido por: sarcopenia, disfunción inmunológica y desregulación neuroendócrina. La sarcopenia es definida como una disminución de la fuerza y de la potencia muscular, donde los músculos respiratorios también son afectados. El objetivo fue comparar la fuerza muscular respiratoria (FMR) en añosas residentes en la comunidad, clasificadas como no frágiles (NF), pre-frágiles (PF) y frágiles (F) y correlacionar la FMR con la fuerza de prensión manual (FPM). El estudio fue del tipo transversal, con una muestra de conveniencia compuesta por 106 añosas. Las participantes fueron clasificadas en cuanto al fenotipo de fragilidad. La FMR fue evaluada por medio de la presión inspiratoria máxima (PImáx) y de la presión expiratoria máxima (PEmáx). Fueron encontradas diferencias significativas de la FMR entre los grupos NF y F (PImáx: p=0,001 y PEmáx: p<0,001) y entre los grupos PF y F (PImáx: p<0,001 y PEmáx: p<0,001). En relación a la FPM, fueron observadas diferencias significativas entre todos los grupos (p<0,001). Hubo correlación entre FMR y FPM apenas en el grupo frágil. De esta forma, la FPM puede ser importante en la práctica clínica para diferenciar los subgrupos de fragilidad e identificar la pérdida de fuerza muscular, incluyendo la pérdida de la FMR...

Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis.

BACKGROUND: Carnitine insufficiency is responsible for various co-morbid conditions in maintenance hemodialysis (MHD) patients. L-carnitine supplementation is expected to improve the quality of life (QoL) of patients on MHD. AIMS: To study the effect of L-carnitine supplementation on QoL of Indian patients on MHD. SETTING AND DESIGN: This was a single (patient) blind, randomized, placebo-controlled clinical trial conducted on patients on MHD attending hemodialysis unit of the study center. MATERIALS AND METHODS: Twenty patients on MHD suffering from hemodialysis-related symptoms were randomly assigned to receive intravenous L-carnitine 20 mg/kg or placebo after every dialysis session for 8 weeks. SF36 (Short Form with 36 questions) score for QoL, laboratory investigations and dialysis related symptoms were recorded at baseline and after 8 weeks. Improvement in QoL, laboratory parameters and dialysis related symptoms in the two groups after 8 weeks was compared. STATISTICAL ANALYSIS USED: Depending on normality of data, unpaired T test or Mann Whitney U test was used for comparison of change (8 weeks-baseline) in SF36 scores and laboratory parameters observed in the two groups. RESULTS: L-carnitine supplementation increased total SF36 score by 18.29 +/- 12.71 (95% CI: 10.41 to 26) while placebo resulted in reduction in total SF36 score by 6.4 +/- 16.39 (95% CI: -16.59 to 3.73). L-carnitine also resulted in significant increase in hemoglobin and serum albumin and decrease in serum creatinine as compared to placebo. More patients were relieved of dialysis related symptoms in L-carnitine group. CONCLUSION: Intravenous L-carnitine supplementation improves QoL in patients on MHD.

A study on the impact of FD-MDT on 200 leprosy patients.

A study was carried out from June 1999 to June 2001 to assess the impact of fixed duration multidrug therapy (FD-MDT) in newly detected cases of leprosy in terms of clinical and neurological improvement and changes in the bacillary index of skin smear for AFB. 200 new leprosy cases (both PB & MB) were started on FD-MDT. Of these 200 cases, 16 were of pure neuritic leprosy. After treatment, out of 184 cases with typical skin lesions of leprosy, all 26 PB cases showed inactivity of skin lesions, and, of the remaining 158 MB cases, 40.5% showed inactivity and 59.5% showed complete resolution of skin lesions. Out of 68 skin smear-positive cases, 42 cases with a BI of < or = 3 became smear-negative, while others showed gradual fall in the BI. Such heavily bacilliferous cases were continued with treatment for 1 more year to prevent relapse. As FD-MDT alone does not cure established sensory and motor impairment, it did not show any change in 19% of the patients presented with permanent sensory motor disturbance. FD-MDT prevents progression of sensory/motor disturbance.